Press release
Soft Tissue Sarcoma Pipeline Review 2024: Clinical Trials Update, Therapies and Key Companies involved by DelveInsight | OncoTherapy Science, Foghorn Therapeutics, C4 Therapeutics, Lyvgen Biopharma Holdings, Chipscreen Biosciences, Monopar Therapeutics
"Soft Tissue Sarcoma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Soft Tissue Sarcoma Market.
The Soft Tissue Sarcoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Soft Tissue Sarcoma Pipeline Report: https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Soft Tissue Sarcoma treatment therapies with a considerable amount of success over the years.
• Soft Tissue Sarcoma companies working in the treatment market are OncoTherapy Science, Inc., Foghorn Therapeutics Inc., C4 Therapeutics, Inc, Lyvgen Biopharma Holdings Limited, Chipscreen Biosciences, Ltd., Monopar Therapeutics, Advenchen Laboratories, LLC, Philogen S.p.A., Monopar Therapeutics, Lytix Biopharma, Jazz Pharmaceuticals, and others, are developing therapies for the Soft Tissue Sarcoma treatment
• Emerging Soft Tissue Sarcoma therapies in the different phases of clinical trials are- OTSA101-DTPA111In, FHD-609, CFT8634, LVGN6051 + Anlotinib, Chiauranib, MNPR 201, AL3818, Fibronum + Doxorubicin, GPX-150, LTX-315, Lurbinectedin, and others are expected to have a significant impact on the Soft Tissue Sarcoma market in the coming years.
• In July 2024, Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage clinical biotechnology company focused on developing proprietary immune-based intratumoral cancer therapies that directly target tumors and enhance immune system recognition, has announced the dosing of the first U.S. patient in its Phase 3 study for treating metastatic sarcoma (NCT06263231). This superiority study evaluates INT230-6 as a monotherapy against three standard-of-care systemic chemotherapy drugs in patients with second or third-line metastatic, recurrent, or inoperable soft tissue sarcomas (STS).
Soft Tissue Sarcoma Overview
Soft tissue sarcoma (STS) refers to a diverse group of cancers that originate in the soft tissues of the body. These tissues encompass muscles, tendons, fat, blood vessels, nerves, and deep skin tissues.
Get a Free Sample PDF Report to know more about Soft Tissue Sarcoma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Soft Tissue Sarcoma Drugs Under Different Phases of Clinical Development Include:
• OTSA101-DTPA111In: OncoTherapy Science, Inc.
• FHD-609: Foghorn Therapeutics Inc.
• CFT8634: C4 Therapeutics, Inc
• LVGN6051 + Anlotinib: Lyvgen Biopharma Holdings Limited
• Chiauranib: Chipscreen Biosciences, Ltd.
• MNPR 201: Monopar Therapeutics
• AL3818: Advenchen Laboratories, LLC
• Fibronum + Doxorubicin: Philogen S.p.A.
• GPX-150: Monopar Therapeutics
• LTX-315: Lytix Biopharma
• Lurbinectedin: Jazz Pharmaceuticals
Soft Tissue Sarcoma Route of Administration
Soft Tissue Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Soft Tissue Sarcoma Molecule Type
Soft Tissue Sarcoma Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Soft Tissue Sarcoma Pipeline Therapeutics Assessment
• Soft Tissue Sarcoma Assessment by Product Type
• Soft Tissue Sarcoma By Stage and Product Type
• Soft Tissue Sarcoma Assessment by Route of Administration
• Soft Tissue Sarcoma By Stage and Route of Administration
• Soft Tissue Sarcoma Assessment by Molecule Type
• Soft Tissue Sarcoma by Stage and Molecule Type
DelveInsight's Soft Tissue Sarcoma Report covers around 130+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Soft Tissue Sarcoma product details are provided in the report. Download the Soft Tissue Sarcoma pipeline report to learn more about the emerging Soft Tissue Sarcoma therapies at:
https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Soft Tissue Sarcoma Therapeutics Market include:
Key companies developing therapies for Soft Tissue Sarcoma are - AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, and others.
Soft Tissue Sarcoma Pipeline Analysis:
The Soft Tissue Sarcoma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Soft Tissue Sarcoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Soft Tissue Sarcoma Treatment.
• Soft Tissue Sarcoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Soft Tissue Sarcoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Soft Tissue Sarcoma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Soft Tissue Sarcoma drugs and therapies-
https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Soft Tissue Sarcoma Pipeline Market Drivers
• Increase in Cancer Cases, rising Involvement of Clinical Trials are some of the important factors that are fueling the Soft Tissue Sarcoma Market.
Soft Tissue Sarcoma Pipeline Market Barriers
• However, side-Effects of Soft Tissue Sarcoma Drugs, increasing Cost of Treatments and other factors are creating obstacles in the Soft Tissue Sarcoma Market growth.
Scope of Soft Tissue Sarcoma Pipeline Drug Insight
• Coverage: Global
• Key Soft Tissue Sarcoma Companies: OncoTherapy Science, Inc., Foghorn Therapeutics Inc., C4 Therapeutics, Inc, Lyvgen Biopharma Holdings Limited, Chipscreen Biosciences, Ltd., Monopar Therapeutics, Advenchen Laboratories, LLC, Philogen S.p.A., Monopar Therapeutics, Lytix Biopharma, Jazz Pharmaceuticals, and others
• Key Soft Tissue Sarcoma Therapies: OTSA101-DTPA111In, FHD-609, CFT8634, LVGN6051 + Anlotinib, Chiauranib, MNPR 201, AL3818, Fibronum + Doxorubicin, GPX-150, LTX-315, Lurbinectedin, and others
• Soft Tissue Sarcoma Therapeutic Assessment: Soft Tissue Sarcoma current marketed and Soft Tissue Sarcoma emerging therapies
• Soft Tissue Sarcoma Market Dynamics: Soft Tissue Sarcoma market drivers and Soft Tissue Sarcoma market barriers
Request for Sample PDF Report for Soft Tissue Sarcoma Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Soft Tissue Sarcoma Report Introduction
2. Soft Tissue Sarcoma Executive Summary
3. Soft Tissue Sarcoma Overview
4. Soft Tissue Sarcoma- Analytical Perspective In-depth Commercial Assessment
5. Soft Tissue Sarcoma Pipeline Therapeutics
6. Soft Tissue Sarcoma Late Stage Products (Phase II/III)
7. Soft Tissue Sarcoma Mid Stage Products (Phase II)
8. Soft Tissue Sarcoma Early Stage Products (Phase I)
9. Soft Tissue Sarcoma Preclinical Stage Products
10. Soft Tissue Sarcoma Therapeutics Assessment
11. Soft Tissue Sarcoma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Soft Tissue Sarcoma Key Companies
14. Soft Tissue Sarcoma Key Products
15. Soft Tissue Sarcoma Unmet Needs
16 . Soft Tissue Sarcoma Market Drivers and Barriers
17. Soft Tissue Sarcoma Future Perspectives and Conclusion
18. Soft Tissue Sarcoma Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
Soft Tissue Sarcoma Market https://www.delveinsight.com/report-store/soft-tissue-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Soft Tissue Sarcoma Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Soft Tissue Sarcoma Epidemiology https://www.delveinsight.com/report-store/soft-tissue-sarcoma-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Soft Tissue Sarcoma Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
• Implantable Cardioverter Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Monkeypox Market: https://www.delveinsight.com/report-store/monkeypox-market
• Antibody Drug Conjugate Market: https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Tbi Market: https://www.delveinsight.com/report-store/traumatic-brain-injury-market
• Indwelling Catheters Market: https://www.delveinsight.com/report-store/indwelling-catheters-market
• Hyperlipidemia Market: https://www.delveinsight.com/report-store/hyperlipidemia-market
• Inflammatory Bowel Disease Market: https://www.delveinsight.com/report-store/crohns-disease-cd-market
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Soft Tissue Sarcoma Pipeline Review 2024: Clinical Trials Update, Therapies and Key Companies involved by DelveInsight | OncoTherapy Science, Foghorn Therapeutics, C4 Therapeutics, Lyvgen Biopharma Holdings, Chipscreen Biosciences, Monopar Therapeutics here
News-ID: 3816740 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Soft
Soft Drink Concentrates Market
Introduction
The soft drink concentrates market plays a pivotal role in the global beverage industry. These concentrates are primarily used to prepare soft drinks, offering a cost-effective and efficient way for manufacturers to produce various beverages. Soft drink concentrates are essentially flavored syrups or powders that, when mixed with water or carbonated water, create popular soft drinks. The market for these concentrates has seen remarkable growth in recent years, driven by…
Soft Robot Technology Market Upcoming Trend & Positions 2027 | Cyberdyne, Soft R …
Soft Robot Technology Market Strengths, Weaknesses, Opportunities, and Threats analysis.
Demanding Market Research Report on Global Soft Robot Technology Market conducted by a team of industry specialists. The report covers briefly the products or services in the market and their application. The report also provides data on the technological advancements taking place in the Soft Robot Technology market, helping the market vendors to increase their business productivity and operational efficiency. The…
Global Motor Soft Starter Market, Global Motor Soft Starter Industry, Market Rev …
The Motor soft starter has remarkable application in numerous end-use industries like oil & gas, mining and power generation trades. It supports in lessening the inflow current formed whereas motor start up and consequently boost the extending and proficiency of motor. Along with this, it knowingly assistances in governing motor acceleration which outcomes in safety of motor from much impairment while in complete procedure. It is an apparatus that is…
Soft Touch Film and Soft Touch Lamination Film Market Size, Share, Development b …
Global Info Research offers a latest published report on Soft Touch Film and Soft Touch Lamination Film Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Soft Touch Film and Soft Touch Lamination Film players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in…
Soft Skills Management Market - Increasing Demand For Cloud-Based Soft Skill Tra …
According to a new market report published by Transparency Market Research, the global soft skills management market was valued at US$ 11,289.7 Mn in 2016 and is expected to expand at a CAGR of 11.9% from 2018 to 2026, reaching US$ 33,736.1 Mn by the end of the forecast period. According to the report, the global soft skills management market will continue to be influenced by a range of macroeconomic…
Suma Soft
Texas (USA), Canada (Toronto) & India (Business Network)— Suma Soft’s BPO for companies in USA, Canada and UK efficiently streamline business processes. Suma Soft has developed an integrated back-office system that assists these companies giving them round the clock support.
Credibility & Certification :
Suma Soft is an ISO 27001 and 9001 certified company which gives paramount importance to security, accuracy and quality while delivering BPO support services. We have a…
